Merchant Scientists: Deal Structuring and Pavement Pounding Are Part of Technology Transfer

Richard Gill Richard Gill runs the biosciences division of a global technology transfer company, calling himself "a mercenary technologist." It's an aggressive line of work--mining unsung discoveries at universities, drug companies, and eccentric inventors' garages; obtaining licensing agreements; and getting finished product out into the marketplace. "I use harsher language to describe what I do than 'merchant scientist,'" the popular moniker for his job, says Gill, the senior vice president

Written byArielle Emmett
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share


Richard Gill
Richard Gill runs the biosciences division of a global technology transfer company, calling himself "a mercenary technologist." It's an aggressive line of work--mining unsung discoveries at universities, drug companies, and eccentric inventors' garages; obtaining licensing agreements; and getting finished product out into the marketplace. "I use harsher language to describe what I do than 'merchant scientist,'" the popular moniker for his job, says Gill, the senior vice president and general manager of biosciences at BTG International Inc., Gulph Mills, Pa. "When we [employ] folks, we're looking for someone who understands technology, but is not a technojock. We want someone to drive the technology into product."

A United Kingdom-based company, BTG holds more than 8,500 patents in 250 different technologies. Gill is one of a team of 40 scientists, patent attorneys, and finance and business people at BTG in the United States (the London office has 140), all of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies